Lutonix
Company

Last deal

$10M

Amount

Series C

Stage

13.12.2010

Date

3

all rounds

$35M

Total amount

General

About Company
Lutonix DCB delivers paclitaxel to the arterial wall in a single, short inflation.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2007

Number of employees

Company Type

For Profit

Last funding type

Series C

IPO status

Private

Description

Lutonix DCB is a drug-coated balloon catheter that treats vascular disease in the coronary and peripheral arteries. The balloon contains a special coating of paclitaxel and a proprietary carrier that facilitates the drug's transfer to the arterial wall upon inflation. This allows for a therapeutic dose to be delivered to the artery wall while keeping the dose of paclitaxel on the balloon as low as possible, minimizing systemic drug exposure and maximizing safety. Lutonix DCB's proprietary formulation and coating are designed to maximize efficacy without sacrificing safety, resulting in a decrease in the incidence of restenosis and improved patency in peripheral and coronary vessels.
Contacts